FAQs about Mayzent
Mayzent was approved by the U.S. Food and Drug Administration in March 2019 to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
Animal studies suggest that Mayzent can cause damage to a developing fetus, so patients should inform their healthcare provider if they are pregnant or planning to become pregnant. Effective birth control methods are recommended to all women of childbearing potential while on Mayzent and for 10 days after ceasing treatment.
Interactions between alcohol and Mayzent have not been reported. However, both can cause damage to the liver, and alcohol is known to sometimes exacerbate disease symptoms or interfere with medications. It is recommended that patients on Mayzent discuss with their healthcare team whether it is safe for them to drink alcohol.
Mayzent works rapidly to reduce circulating immune cells, with effects seen in the first few hours of treatment, but it could take several months before a person notices clinical effects. As the disease manifests differently in each person, and responses to treatment may also vary, patients should discuss with their care team how Mayzent could help in their specific case.
Neither hair loss nor weight gain has been reported in clinical trials as side effects of Mayzent. Patients are advised to speak with their healthcare provider if they experience any unusual symptoms while on the medication.
Related Articles